Phase I Study of Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
Summary
The purpose of this phase I study is to evaluate the safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab after adjuvant standard of care treatment in atients with resected PDAC and mismatch repair (MMR)-p colorectal cancer (CRC).
General Information
NCT#: NCT04117087
Study ID: J1994
Trial Phase: Phase I
Trial Sponsor: Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Ipilimumab, Hiltonol®, Nivolumab
Sign In